Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ATR-04

Other · developed by Azitra

Phase 1/2 Most advanced trial (none active)

AZTR Developer

1 Registered trials

What is ATR-04?

ATR-04 is a formulated product containing lyophilized SEΔΔΔ, a genetically modified Staphylococcus epidermidis that is auxotrophic to D-alanine. It is studied in papulopustular rosacea.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Other
Therapy area: Dermatology
Developer: Azitra Inc. (AZTR)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04731259	Phase 1/2	Epidermal Growth Factor	Withdrawn	AZTR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Epidermal Growth FactorPapulopustular Rosacea

More from Azitra

ATR12-351 Phase 1

Sources

ClinicalTrials.gov NCT04731259

Updated Oct 11, 2026. Something wrong or missing? Report it on the AZTR page.

Follow AZTR, the company behind ATR-04

See AZTR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AZTR catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z